Evidence map›Paper›PMID 33393992›Full record

ArticleClinical chemistry2021

Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response Monitoring.

Jared C Nesvet, Katie A Antilla, Danielle S Pancirer, Alexander X Lozano, Jordan S Preiss, Weijie Ma, Aihua Fu, Seung-Min Park, Sanjiv S Gambhir, Alice C Fan and 6 more

Erratum issuedOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Magnetic nanoparticles for cancer theranostics.Biomedical physics & engineering express · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Jared C NesvetDepartment of Chemistry, Stanford University, Stanford, CA, USA.
Katie A AntillaDepartment of Chemical Engineering, Stanford University, Stanford, CA, USA.
Danielle S PancirerStanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Alexander X LozanoDepartment of Materials Science and Engineering, Stanford University, Stanford, CA, USA.
Jordan S PreissStanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Weijie MaDepartment of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.
Aihua FuNvigen Inc, San Jose, CA, USA.
Seung-Min ParkDepartment of Radiology, Stanford University School of Medicine, Stanford, CA, USA.
Sanjiv S GambhirDepartment of Radiology, Stanford University School of Medicine, Stanford, CA, USA.
Alice C FanDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Joel W NealStanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Sukhmani K PaddaStanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Millie DasStanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Tianhong LiDepartment of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.
Heather A WakeleeStanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Shan X WangDepartment of Materials Science and Engineering, Stanford University, Stanford, CA, USA.
Stanford University · USNvigen (United States) · USUC Davis Comprehensive Cancer CenterUniversity of California, Davis · USUniversity of Toronto · CAVA Palo Alto Health Care System · US

Funding

Nano Characterization and Nano Fabrication CoreU54CA199075 · NCI · STANFORD UNIVERSITY · PI FAN, ALICE CHEN · 2015 to 2019
$9.6M
Graduate Training Program in BiotechnologyT32GM008412 · NIGMS · STANFORD UNIVERSITY · PI COCHRAN, JENNIFER R · 1991 to 2020
$5.5M
BLRD VA I01 BX003895NCI NIH HHS U54 CA199075NIGMS NIH HHS T32 GM008412
6 · The paper itself

Abstract

backgroundLiquid biopsy circulating tumor DNA (ctDNA) mutational analysis holds great promises for precision medicine targeted therapy and more effective cancer management. However, its wide adoption is hampered by high cost and long turnaround time of sequencing assays, or by inadequate analytical sensitivity of existing portable nucleic acid tests to mutant allelic fraction in ctDNA.

methodsWe developed a ctDNA Epidermal Growth Factor Receptor (EGFR) mutational assay using giant magnetoresistive (GMR) nanosensors. This assay was validated in 36 plasma samples of non-small cell lung cancer patients with known EGFR mutations. We assessed therapy response through follow-up blood draws, determined concordance between the GMR assay and radiographic response, and ascertained progression-free survival of patients.

resultsThe GMR assay achieved analytical sensitivities of 0.01% mutant allelic fraction. In clinical samples, the assay had 87.5% sensitivity (95% CI = 64.0-97.8%) for Exon19 deletion and 90% sensitivity (95% CI = 69.9-98.2%) for L858R mutation with 100% specificity; our assay detected T790M resistance with 96.3% specificity (95% CI = 81.7-99.8%) with 100% sensitivity. After 2 weeks of therapy, 10 patients showed disappearance of ctDNA by GMR (predicted responders), whereas 3 patients did not (predicted nonresponders). These predictions were 100% concordant with radiographic response. Kaplan-Meier analysis showed responders had significantly (P < 0.0001) longer PFS compared to nonresponders (N/A vs. 12 weeks, respectively).

conclusionsThe GMR assay has high diagnostic sensitivity and specificity and is well suited for detecting EGFR mutations at diagnosis and noninvasively monitoring treatment response at the point-of-care.

Indexed as

Biosensing TechniquesCarcinoma, Non-Small-Cell LungLung NeoplasmsAcrylamidesAgedAniline CompoundsCirculating Tumor DNADNA Mutational AnalysisDrug MonitoringErbB ReceptorsFemaleHumansIndolesLiquid BiopsyMaleMiddle AgedAcrylamidesAniline CompoundsCirculating Tumor DNAErbB ReceptorsIndolesosimertinibProtein Kinase InhibitorsProtein-Tyrosine KinasesPyrimidines

Identifiers

PMID33393992
PMCPMC12118574
OpenAlexW3118553886

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.